RXRX Stock Analysis: Recursion Pharmaceuticals | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 2.483m USD | 12M Return: -26.2% | US75629V1044 | Charts, Fundamentals & Technical Analysis

Oncology, Rare Diseases, Drug Discovery, Hematology
Total Rating 17
Safety 28
Buy Signal -0.74
Biotechnology
Industry Rotation: -19.5
Market Cap: 2.48B
Avg Turnover: 92.4M
Risk 3d forecast
Volatility110%
VaR 5th Pctl17.7%
VaR vs Median-2.27%
Reward TTM
Sharpe Ratio-0.09
Rel. Str. IBD56.7
Rel. Str. Peer Group50.2
Character TTM
Beta2.666
Beta Downside3.081
Hurst Exponent0.505
Drawdowns 3y
Max DD81.70%
CAGR/Max DD-0.15
CAGR/Mean DD-0.21
EPS (Earnings per Share) EPS (Earnings per Share) of RXRX over the last years for every Quarter: "2021-09": -0.28, "2021-12": -0.38, "2022-03": -0.33, "2022-06": -0.38, "2022-09": -0.35, "2022-12": -0.3, "2023-03": -0.34, "2023-06": -0.38, "2023-09": -0.43, "2023-12": -0.42, "2024-03": -0.39, "2024-06": -0.4, "2024-09": -0.34, "2024-12": -0.53, "2025-03": -0.5, "2025-06": -0.41, "2025-09": -0.36, "2025-12": -0.21, "2026-03": -0.22, "2026-06": -0.25,
Last SUE: -0.32
Qual. Beats: 0
Revenue Revenue of RXRX over the last years for every Quarter: 2021-09: 2.5, 2021-12: 2.5, 2022-03: 5.299, 2022-06: 7.653, 2022-09: 13.053, 2022-12: 13.676, 2023-03: 12.134, 2023-06: 11.016, 2023-09: 10.102, 2023-12: 10.624, 2024-03: 13.491, 2024-06: 14.404, 2024-09: 26.082, 2024-12: 4.511, 2025-03: 14.745, 2025-06: 19.103, 2025-09: 5.175, 2025-12: 35.538, 2026-03: 6.472, 2026-06: 7.67,
Rev. CAGR: 12.45%
Rev. Trend: 57.4%
Last SUE: -0.50
Qual. Beats: 0

Warnings

Strong Share Dilution
Interest Coverage Ratio Critical
Altman Z'' In Financial Distress Zone
Fakeout

Tailwinds

No distinct edge detected

Seasonality 5.4 years of data

Jan +6.7% 25
Feb +3.5% 0
Mar -18.2% 57
Apr +2.0% 9
May +12.1% 30
Jun -0.1% 9
Jul +17.6% 40
Aug -4.5% 10
Sep -0.3% 0
Oct +0.2% 18
Nov +4.4% 0
Dec -7.3% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: RXRX Recursion Pharmaceuticals

Recursion Pharmaceuticals (RXRX) is a clinical-stage biotechnology company founded in 2013 and headquartered in Salt Lake City, Utah. The company applies an integrated approach combining biology, chemistry, automation, data science, and engineering to industrialize drug discovery, operating primarily in the United States and the United Kingdom.

The companys pipeline includes multiple candidates in Phase 1/1b/2 clinical trials, such as REC-4881 for familial adenomatous polyposis, REC-617 for advanced solid tumors, REC-1245 for biomarker-enriched solid tumors and lymphoma, REC-3565 for B-cell malignancies, and REC-4539, an LSD1 inhibitor targeting solid tumors and hematologic cancers. Preclinical programs include REC-7735 for HR+ breast cancer and REC-102 for hypophosphatasia.

Recursion has established collaborations and agreements with major pharmaceutical companies including Roche & Genentech, Sanofi, Bayer, Tempus, and Takeda. As a clinical-stage biotech, the company focuses on platform-driven drug discovery rather than approved product revenues, which is typical of the biotechnology sub-industry where firms often rely on partnerships and capital markets to fund lengthy R&D and clinical development cycles before reaching commercialization.

Headlines to Watch Out For
  • REC-617 and REC-1245 Phase 2 data readouts near
  • Roche and Sanofi milestone payments support revenue
  • Cash burn from expanding pipeline trials pressures liquidity
Piotroski VR-10 (Strict) 0.0
Net Income: -518.9m TTM > 0 and > 6% of Revenue
FCF/TA: -0.29 > 0.02 and ΔFCF/TA 1.06 > 1.0
NWC/Revenue: 881.6% < 20% (prev 656.6%; Δ 224.9% < -1%)
CFO/TA -0.29 > 3% & CFO -350.5m > Net Income -518.9m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 5.03 > 1.5 & < 3
Outstanding Shares: last quarter (532.5m) vs 12m ago 27.58% < -2%
Gross Margin: -46.66% > 18% (prev -3.76%; Δ -42.90% > 0.5%)
Asset Turnover: 4.36% > 50% (prev 4.95%; Δ -0.59% > 0%)
Interest Coverage Ratio: -347.8 > 6 (EBIT TTM -522.8m / Interest Expense TTM 1.50m)
Altman Z'' -3.20
A: 0.40 (Total Current Assets 603.5m - Total Current Liabilities 119.9m) / Total Assets 1.21b
B: -1.92 (Retained Earnings -2.32b / Total Assets 1.21b)
C: -0.42 (EBIT TTM -522.8m / Avg Total Assets 1.26b)
D: 3.07 (Book Value of Equity 915.0m / Total Liabilities 297.7m)
Altman-Z'' = -3.20 = D
Beneish M -3.36
DSRI: 0.78 (Receivables 14.4m/21.6m, Revenue 54.9m/64.4m)
GMI: 1.00 (fallback, negative margins)
AQI: 0.95 (AQ_t 0.38 / AQ_t-1 0.40)
SGI: 0.85 (Revenue 54.9m / 64.4m)
TATA: -0.14 (NI -518.9m - CFO -350.5m) / TA 1.21b)
Beneish M = -3.36 (Cap -4..+1) = AA
What is the price of RXRX shares?

As of October 11, 2026, the stock is trading at USD 4.36 with a total of 35,308,952 shares traded. Over the past week, the price has changed by +5.83%, over one month by +35.61%, over three months by +15.96% and over the past year by -26.23%.

Current recommended Stop Loss: 3.70 (which is 15.1% or 1.9 ATR below the current price).

Is RXRX a buy, sell or hold?

Recursion Pharmaceuticals has received a consensus analysts rating of 3.57. Therefore, it is recommended to hold RXRX.

  • StrongBuy: 1
  • Buy: 2
  • Hold: 4
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the RXRX price?
Analysts Target Price 7.2 65.6%
Recursion Pharmaceuticals (RXRX) - Fundamental Data Overview as of 08 October 2026
Market Cap USD = 2.48b (2.48b USD * 1.0 USD.USD)
P/S = 45.2628
P/B = 2.1685
Revenue TTM = 54.9m USD
EBIT TTM = -522.8m USD
EBITDA TTM = -444.4m USD
Long Term Debt = 4.75m USD (from longTermDebt, last quarter)
Short Term Debt = 22.7m USD (from shortTermDebt, last quarter)
Debt = 114.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 52.4m
Net Debt = -431.4m USD (calculated: Debt 114.3m - CCE 545.7m)
Enterprise Value = 2.05b USD (2.48b + Debt 114.3m - CCE 545.7m)
Interest Coverage Ratio = -347.8 (Ebit TTM -522.8m / Interest Expense TTM 1.50m)
EV/FCF = -5.79x (Enterprise Value 2.05b / FCF TTM -354.3m)
FCF Yield = -17.27% (FCF TTM -354.3m / Enterprise Value 2.05b)
 FCF Margin = -645.8% (FCF TTM -354.3m / Revenue TTM 54.9m)
 Net Margin = -945.9% (Net Income TTM -518.9m / Revenue TTM 54.9m)
 Gross Margin = -46.66% ((Revenue TTM 54.9m - Cost of Revenue TTM 80.5m) / Revenue TTM)
Gross Margin QoQ = -49.82% (prev -92.99%)
Tobins Q-Ratio = 1.69 (Enterprise Value 2.05b / Total Assets 1.21b)
Interest Expense / Debt = 1.31% (Interest Expense 1.50m / Debt 114.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -413.0m (EBIT -522.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.03 (Total Current Assets 603.5m / Total Current Liabilities 119.9m)
Debt / Equity = 0.12 (Debt 114.3m / totalStockholderEquity, last quarter 915.0m)
 Debt / EBITDA = 0.97 (negative EBITDA) (Net Debt -431.4m / EBITDA -444.4m)
 Debt / FCF = 1.22 (negative FCF - burning cash) (Net Debt -431.4m / FCF TTM -354.3m)
 Total Stockholder Equity = 1.03b (last 4 quarters mean from totalStockholderEquity)
RoA = -41.26% (Net Income -518.9m / Total Assets 1.21b)
RoE = -50.41% (Net Income TTM -518.9m / Total Stockholder Equity 1.03b)
RoCE = -50.55% (EBIT -522.8m / Capital Employed (Equity 1.03b + L.T.Debt 4.75m))
 RoIC = -37.12% (negative operating profit) (NOPAT -413.0m / Invested Capital 1.11b)
 WACC = 14.73% (E(2.48b)/V(2.60b) * Re(15.36%) + D(114.3m)/V(2.60b) * Rd(1.31%) * (1-Tc(0.21)))
Discount Rate = 15.36% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 98.32 | Cagr: 43.56%
 [DCF] Fair Price = unknown (Cash Flow -354.3m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.32 | # QB: 0
Revenue Correlation: 57.41 | Revenue CAGR: 12.45% | SUE: -0.50 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.23 | Chg30d=-0.74% | Revisions=-25% | Analysts=6
EPS current Year (2026-12-31): EPS=-0.93 | Chg30d=-0.93% | Revisions=-25% | GrowthEPS=+35.3% | GrowthRev=-48.0%
EPS next Year (2027-12-31): EPS=-0.90 | Chg30d=-0.80% | Revisions=-25% | GrowthEPS=+3.2% | GrowthRev=+35.0%
[Analyst] Revisions Ratio: -50% (up=0, down=3)